LONAFARNIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H31Br2ClN4O2
Molecular Weight	638.822
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LONAFARNIB

Structure Search

SMILES

NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=C3C(Br)=CC(Cl)=C5)C=C(Br)C=N4)CC1

InChI

InChIKey=DHMTURDWPRKSOA-RUZDIDTESA-N

InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C27H31Br2ClN4O2
Molecular Weight	638.822
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:37:30 UTC 2023` Edited by `admin` on `Sat Dec 16 04:37:30 UTC 2023`
Record UNII	IOW153004F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LONAFARNIB

Official Name

English

SCH-66336

Code

English

SARASAR

Brand Name

English

SCH66336

Code

English

LONAFARNIB [MI]

Common Name

English

SCH 66336

Code

English

1-PIPERIDINECARBOXAMIDE, 4-(2-(4-((11R-3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YL)-1-PIPERIDINYL)-2-OXOETHYL)-

Common Name

English

LONAFARNIB [ORANGE BOOK]

Common Name

English

ZOKINVY

Brand Name

English

LONAFARNIB [USAN]

Common Name

English

(+)-4-(2-(4-(11R)-3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YL)-PIPERIDIN-1-YL))-2-OXOETHYL)-PIPERIDINE-1-CARBOXAMIDE

Common Name

English

Lonafarnib [WHO-DD]

Common Name

English

lonafarnib [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

411713

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

EU-Orphan Drug

EU/3/18/2118

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

NCI_THESAURUS

C2020

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

FDA ORPHAN DRUG

333411

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

Code System Code Type Description

WIKIPEDIA

LONAFARNIB

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

PUBCHEM

148195

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

NCI_THESAURUS

C1829

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

SMS_ID

100000087350

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

EPA CompTox

DTXSID90172927

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

CAS

193275-84-2

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

MERCK INDEX

m6892

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

Merck Index

FDA UNII

IOW153004F

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

RXCUI

2467553

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

USAN

MM-63

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

MESH

C115354

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

EVMPD

SUB21038

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

DAILYMED

IOW153004F

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

ChEMBL

CHEMBL298734

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

DRUG BANK

DB06448

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

CHEBI

47097

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

INN

8191

Created by admin on Sat Dec 16 04:37:31 UTC 2023 , Edited by admin on Sat Dec 16 04:37:31 UTC 2023

PRIMARY

Related Record Type Details


					805SU96HKF

CYTOCHROME P450 3A5

METABOLIC ENZYME -> SUBSTRATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

Lonafarnib is a potent CYP3A time-dependent and mechanism-based inhibitor.

Interaction Type:

TIME-DEPENDENT INHIBITION

Qualification:

POTENCY


					AIN96D6SGL

OATP1B1

TRANSPORTER -> INHIBITOR


					VK4SQL11C0

CYTOCHROME P450 1A2

METABOLIC ENZYME -> SUBSTRATE

Comments:

IN VITRO


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> SUBSTRATE


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> INHIBITOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Comments:

Lonafarnib is likely a marginal substrate of P-gp.


					UR5J2T2G7T

FARNESYLTRANSFERASE

TARGET -> INHIBITOR

Amount:


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> SUBSTRATE

Comments:

IN VITRO


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> SUBSTRATE

Comments:

IN VITRO


					03BYF220B6

CYTOCHROME P450 2E1

METABOLIC ENZYME -> SUBSTRATE

Comments:

IN VITRO

Amount:


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> INHIBITOR


					246D9TQ2XG

CYTOCHROME P450 2A6

METABOLIC ENZYME -> SUBSTRATE

Comments:

IN VITRO


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> INHIBITOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

In vitro plasma protein binding of lonafarnib was greater than or equal to 99% over the concentration range between 0.5 to 40.0 μg/mL.

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR


					66DDF797LP

OATP-8

TRANSPORTER -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR

Related Record Type Details


					J8HBS2S2PW

2-HYDROXY-LONAFARNIB, (1-PIPERIDINECARBOXAMIDE RING)

METABOLITE -> PARENT


					C0533KA81Q

1(2H)-PYRIDINECARBOXAMIDE, 4-(2-(4-((11R)-3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YL)-1-PIPERIDINYL)-2-OXOETHYL)-3,4-DIHYDRO-

METABOLITE -> PARENT

Related Record Type Details


					IOW153004F

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC				IN HEALTHY SUBJECTS ORAL ADMINISTRATION DOSE AT STEADY-STATE

Tmax	PHARMACOKINETIC				AT STEADY-STATE DOSE ORAL ADMINISTRATION TWICE DAILY

Volume of Distribution	PHARMACOKINETIC				AT STEADY-STATE ORAL ADMINISTRATION TWICE DAILY IN HEALTHY SUBJECTS

Biological Half-life	PHARMACOKINETIC				IN HEALTHY SUBJECTS ORAL ADMINISTRATION TWICE DAILY

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION TWICE DAILY AT STEADY-STATE DOSE